What does this mean for Celebrex or Bextra, the other two drugs in the class known as COX-2 inhibitors?
In light of the Vioxx study findings, several top scientists have stated that the finding of an elevated risk of heart attacks and strokes applies to all COX-2 inhibitors. Clinical trials of Celebrex and Bextra did not reveal the same problems as Vioxx because participants were allowed to take aspirin, which has proved to reduce the risk of cardiovascular problems. Pfizer, maker of Celebrex and the less-prescribed Bextra, stands by its products.
